

15 May 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche's immunotherapy ambitions take a hit; Biogen's CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 13 May 2022, including: [*Pfizer Inc.*](#) to boost migraine presence via M&A; [*Roche Holding AG*](#)'s immunotherapy ambitions take a hit; [*Biogen, Inc.*](#)'s CEO search gets more complicated; Stoffels lays out new strategy for [*Galapagos NV*](#); and mixed results for Japanese majors.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [*Apple Podcasts*](#), [*Google Podcasts*](#), [*SoundCloud*](#), [*TuneIn*](#) and [*Spotify Podcasts*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[*Pfizer To Put Big Marketing Muscle Behind Migraine With Biohaven Purchase*](#)" - Scrip, 10 May, 2022.)

(Also see "[*Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails*](#)" - Scrip, 11 May, 2022.)

(Also see "[*Lecanemab Filing Complicates Biogen's Hunt For New CEO*](#)" - Scrip, 11 May, 2022.)

(Also see "[*Stoffels Sets Out Strategy To Save Galapagos*](#)" - Scrip, 9 May, 2022.)

(Also see "[*Mainstays Give And Take As Major Japan Firms Report Results*](#)" - Scrip, 11 May, 2022.)

[*Click here to explore this interactive content online*](#) ✎